1 day+0.76%
Current year+1.92%
Current year 2.5
Extreme 2.5
2.65
1 year 1.65
Extreme 1.65
2.66
3 years 0.89
Extreme 0.89
8.49
5 years 0.89
Extreme 0.89
28.24
10 years 0.89
Extreme 0.89
46.44
Manager TitleAgeSince
President - 28/01/2026
Director TitleAgeSince
Director/Board Member - 28/01/2026
Date Insider Type Main position Quantity % Market Cap. Importance
28/01/26 Issuer sale

Chief Executive Officer

11,67,586 2.7085%
28/01/26
BVF Partners LP
TenderCompany 1,01,66,943 23.5846%
28/01/26 Issuer sale

Chairman

7,500 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-.--% - - 11Cr
-3.10%-3.43%+36.29%+67.69% 6.53TCr
+0.33%+7.26%+11.51%+77.95% 5.46TCr
+0.16%+3.69%+8.39%+101.27% 5.36TCr
-0.75%+2.13%+23.14%+47.25% 4.5TCr
-1.30%-1.11%+17.77%+120.71% 4.22TCr
+1.26%+2.23%+241.81%+835.31% 3.94TCr
-0.74%-4.84%+14.53%+44.45% 3.27TCr
-2.70%-7.34%+23.17%+0.36% 2.4TCr
+1.11%+17.90%+56.87%+47.78% 2.65TCr
Average -0.51%+1.98%+48.16%+149.20% 4.26TCr
Weighted average by Cap. -0.73%+1.72%+45.16%+148.64%
Logo Repare Therapeutics Inc.
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Employees
129
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Repare Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. RPTX Stock